サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1487527

糖尿病性神経障害市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測

Diabetic Neuropathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日: | 発行: Transparency Market Research | ページ情報: 英文 251 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.78円
糖尿病性神経障害市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測
出版日: 2024年04月04日
発行: Transparency Market Research
ページ情報: 英文 251 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病性神経障害市場- 調査範囲

TMRの糖尿病性神経障害の世界市場に関する調査レポートは、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の糖尿病性神経障害市場の収益と予測を提供しています。また、2024年から2034年までの糖尿病性神経障害の世界市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。1次調査では、主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、糖尿病性神経障害市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書を参照しました。

市場スナップショット
2023年の市場規模 46億米ドル
2034年の市場価値 85億米ドル
CAGR 5.5%

本レポートでは、世界の糖尿病性神経障害市場の競合情勢について掘り下げています。世界の糖尿病性神経障害市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTは、本レポートでプロファイリングされた世界の糖尿病性神経障害市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：市場

第4章 市場概要

  • イントロダクション
  • 市場概要
  • 市場力学
  • 市場分析と予測、2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品・ブランド分析
  • 主要M&A
  • COVID-19パンデミックの産業への影響

第6章 世界市場分析・予測：疾患タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：疾患タイプ別、2020年～2034年
    • 末梢神経障害
    • 自律神経障害
    • 近位神経障害
    • 局所神経障害
  • 市場魅力度分析：疾患タイプ別

第7章 世界市場分析・予測：治療タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：治療タイプ別、2020年～2034年
    • 医薬品
      • 鎮痛薬
        • 外用薬
        • カプサイシン
        • その他
        • オピオイド
        • モルヒネ
        • その他
        • 非ステロイド性抗炎症薬
        • イブプロフェン
        • ナプロキセン
        • その他
      • 抗うつ薬
        • TCA
        • アミトリプチリン
        • イミプラミン
        • その他
        • SNRI
        • デュロキセチン
        • その他
        • SSRI
        • シタロプラム
        • パロキセチン
        • その他
      • 抗けいれん薬
        • ガバペンチン
        • プレガバリン
        • トピマレート
        • その他
      • その他の薬剤
    • 放射線療法
      • TENS
      • その他
    • 理学療法
  • 市場魅力度分析：治療タイプ別

第8章 世界市場分析・予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別、2020年～2034年
    • 病院
    • 診療所
    • 小売薬局
    • オンライン薬局
  • 市場魅力度分析：流通チャネル別

第9章 世界市場分析・予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020年～2034年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 北米市場の分析と予測

第11章 北欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と展望

第14章 中東・アフリカ市場の分析と展望

第15章 競合情勢

  • 市場競合マトリックス（企業階層別・企業規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • Johnson & Johnson（Janssen Global Services, LLC）
    • Boehringer Ingelheim GmbH
    • NeuroMetrix, Inc.
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Lupin Limited
    • Pfizer Inc.
    • Astellas Pharma Inc.
    • Glenmark Pharmaceuticals Ltd.
    • Arbor Pharmaceuticals, LLC
    • Depomed, Inc.
図表

List of Tables

  • Table 01: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2020-2034
  • Table 02: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 03: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 05: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 06: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2020-2034
  • Table 07: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 08: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 09: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2020-2034
  • Table 11: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 12: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2020-2034
  • Table 15: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 16: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 17: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2020-2034
  • Table 19: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 20: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2020-2034
  • Table 23: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 24: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Diabetic Neuropathy Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Diabetic Neuropathy Market Revenue (US$ Mn), by Disorder Type, 2023
  • Figure 03: Global Diabetic Neuropathy Market Value Share, by Disorder Type, 2023
  • Figure 04: Global Diabetic Neuropathy Market Revenue (US$ Mn), by Treatment Type, 2023
  • Figure 05: Global Diabetic Neuropathy Market Value Share, by Treatment Type, 2023
  • Figure 06: Global Diabetic Neuropathy Market Revenue (US$ Mn), by Distribution Channel, 2023
  • Figure 07: Global Diabetic Neuropathy Market Value Share, by Distribution Channel, 2023
  • Figure 08: Global Diabetic Neuropathy Market Value Share, by Region, 2023
  • Figure 09: Global Diabetic Neuropathy Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 10: Global Diabetic Neuropathy Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 11: Global Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Diabetic Neuropathy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 13: Global Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 14: Diabetic Neuropathy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 15: Global Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 16: Global Diabetic Neuropathy Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Diabetic Neuropathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Diabetic Neuropathy Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Diabetic Neuropathy Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Diabetic Neuropathy Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 22: North America Diabetic Neuropathy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 23: North America Diabetic Neuropathy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 24: North America Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 26: North America Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 27: Europe Diabetic Neuropathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Diabetic Neuropathy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Diabetic Neuropathy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Diabetic Neuropathy Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 31: Europe Diabetic Neuropathy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 32: Europe Diabetic Neuropathy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 33: Europe Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 35: Europe Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 36: Asia Pacific Diabetic Neuropathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Diabetic Neuropathy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Diabetic Neuropathy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Diabetic Neuropathy Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 40: Asia Pacific Diabetic Neuropathy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 41: Asia Pacific Diabetic Neuropathy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 42: Asia Pacific Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 44: Asia Pacific Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 45: Latin America Diabetic Neuropathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Diabetic Neuropathy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Diabetic Neuropathy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Diabetic Neuropathy Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 49: Latin America Diabetic Neuropathy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 50: Latin America Diabetic Neuropathy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Latin America Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 53: Latin America Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 54: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Diabetic Neuropathy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Diabetic Neuropathy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Diabetic Neuropathy Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 58: Middle East & Africa Diabetic Neuropathy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 59: Middle East & Africa Diabetic Neuropathy Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 60: Middle East & Africa Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 62: Middle East & Africa Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2024-2034
目次
Product Code: TMRGL2199

Diabetic Neuropathy Market - Scope of Report

TMR's report on the global diabetic neuropathy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global diabetic neuropathy market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global diabetic neuropathy market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the diabetic neuropathy market.

Market Snapshot
Market Value in 2023US$ 4.6 Bn
Market Value in 2034US$ 8.5 Bn
CAGR5.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global diabetic neuropathy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global diabetic neuropathy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global diabetic neuropathy market.

The report delves into the competitive landscape of the global diabetic neuropathy market. Key players operating in the global diabetic neuropathy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global diabetic neuropathy market profiled in this report.

Key Questions Answered in Global diabetic neuropathy Market Report:

  • What is the sales/revenue generated by diabetic neuropathy across all regions during the forecast period?
  • What are the opportunities in the global diabetic neuropathy market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Diabetic Neuropathy Market - Research Objectives and Research Approach

The comprehensive report on the global diabetic neuropathy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global diabetic neuropathy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global diabetic neuropathy market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Diabetic Neuropathy Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Diabetic Neuropathy Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Diabetic Neuropathy Market Analysis and Forecast, by Disorder Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 6.3.1. Peripheral Neuropathy
    • 6.3.2. Autonomic Neuropathy
    • 6.3.3. Proximal Neuropathy
    • 6.3.4. Focal Neuropathy
  • 6.4. Market Attractiveness Analysis, by Disorder Type

7. Global Diabetic Neuropathy Market Analysis and Forecast, by Treatment Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 7.3.1. Drugs
      • 7.3.1.1. Analgesics
        • 7.3.1.1.1. Topical
        • 7.3.1.1.1.1. Capsaicin
        • 7.3.1.1.1.2. Others
        • 7.3.1.1.2. Opioids
        • 7.3.1.1.2.1. Morphine
        • 7.3.1.1.2.2. Others
        • 7.3.1.1.3. NSAIDs
        • 7.3.1.1.3.1. Ibuprofen
        • 7.3.1.1.3.2. Naproxen
        • 7.3.1.1.3.3. Others
      • 7.3.1.2. Antidepressants
        • 7.3.1.2.1. TCAs
        • 7.3.1.2.1.1. Amitriptyline
        • 7.3.1.2.1.2. Imipramine
        • 7.3.1.2.1.3. Others
        • 7.3.1.2.2. SNRIs
        • 7.3.1.2.2.1. Duloxetine
        • 7.3.1.2.2.2. Others
        • 7.3.1.2.3. SSRIs
        • 7.3.1.2.3.1. Citalopram
        • 7.3.1.2.3.2. Paroxetin
        • 7.3.1.2.3.3. Others
      • 7.3.1.3. Anticonvulsants
        • 7.3.1.3.1. Gabapentin
        • 7.3.1.3.2. Pregabalin
        • 7.3.1.3.3. Topimarate
        • 7.3.1.3.4. Others
      • 7.3.1.4. Other Drugs
    • 7.3.2. Radiotherapy
      • 7.3.2.1. TENS
      • 7.3.2.2. Others
    • 7.3.3. Physiotherapy
  • 7.4. Market Attractiveness Analysis, by Treatment Type

8. Global Diabetic Neuropathy Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Retail Pharmacies
    • 8.3.4. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Diabetic Neuropathy Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Diabetic Neuropathy Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 10.3.1. Peripheral Neuropathy
    • 10.3.2. Autonomic Neuropathy
    • 10.3.3. Proximal Neuropathy
    • 10.3.4. Focal Neuropathy
  • 10.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 10.4.1. Drugs
      • 10.4.1.1. Analgesics
        • 10.4.1.1.1. Topical
        • 10.4.1.1.1.1. Capsaicin
        • 10.4.1.1.1.2. Others
        • 10.4.1.1.2. Opioids
        • 10.4.1.1.2.1. Morphine
        • 10.4.1.1.2.2. Others
        • 10.4.1.1.3. NSAIDs
        • 10.4.1.1.3.1. Ibuprofen
        • 10.4.1.1.3.2. Naproxen
        • 10.4.1.1.3.3. Others
      • 10.4.1.2. Antidepressants
        • 10.4.1.2.1. TCAs
        • 10.4.1.2.1.1. Amitriptyline
        • 10.4.1.2.1.2. Imipramine
        • 10.4.1.2.1.3. Others
        • 10.4.1.2.2. SNRIs
        • 10.4.1.2.2.1. Duloxetine
        • 10.4.1.2.2.2. Others
        • 10.4.1.2.3. SSRIs
        • 10.4.1.2.3.1. Citalopram
        • 10.4.1.2.3.2. Paroxetin
        • 10.4.1.2.3.3. Others
      • 10.4.1.3. Anticonvulsants
        • 10.4.1.3.1. Gabapentin
        • 10.4.1.3.2. Pregabalin
        • 10.4.1.3.3. Topimarate
        • 10.4.1.3.4. Others
      • 10.4.1.4. Other Drugs
    • 10.4.2. Radiotherapy
      • 10.4.2.1. TENS
      • 10.4.2.2. Others
    • 10.4.3. Physiotherapy
  • 10.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.5.1. Hospitals
    • 10.5.2. Clinics
    • 10.5.3. Retail Pharmacies
    • 10.5.4. Online Pharmacies
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Disorder Type
    • 10.7.2. By Treatment Type
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Diabetic Neuropathy Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 11.3.1. Peripheral Neuropathy
    • 11.3.2. Autonomic Neuropathy
    • 11.3.3. Proximal Neuropathy
    • 11.3.4. Focal Neuropathy
  • 11.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 11.4.1. Drugs
      • 11.4.1.1. Analgesics
        • 11.4.1.1.1. Topical
        • 11.4.1.1.1.1. Capsaicin
        • 11.4.1.1.1.2. Others
        • 11.4.1.1.2. Opioids
        • 11.4.1.1.2.1. Morphine
        • 11.4.1.1.2.2. Others
        • 11.4.1.1.3. NSAIDs
        • 11.4.1.1.3.1. Ibuprofen
        • 11.4.1.1.3.2. Naproxen
        • 11.4.1.1.3.3. Others
      • 11.4.1.2. Antidepressants
        • 11.4.1.2.1. TCAs
        • 11.4.1.2.1.1. Amitriptyline
        • 11.4.1.2.1.2. Imipramine
        • 11.4.1.2.1.3. Others
        • 11.4.1.2.2. SNRIs
        • 11.4.1.2.2.1. Duloxetine
        • 11.4.1.2.2.2. Others
        • 11.4.1.2.3. SSRIs
        • 11.4.1.2.3.1. Citalopram
        • 11.4.1.2.3.2. Paroxetin
        • 11.4.1.2.3.3. Others
      • 11.4.1.3. Anticonvulsants
        • 11.4.1.3.1. Gabapentin
        • 11.4.1.3.2. Pregabalin
        • 11.4.1.3.3. Topimarate
        • 11.4.1.3.4. Others
      • 11.4.1.4. Other Drugs
    • 11.4.2. Radiotherapy
      • 11.4.2.1. TENS
      • 11.4.2.2. Others
    • 11.4.3. Physiotherapy
  • 11.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.5.1. Hospitals
    • 11.5.2. Clinics
    • 11.5.3. Retail Pharmacies
    • 11.5.4. Online Pharmacies
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Disorder Type
    • 11.7.2. By Treatment Type
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Diabetic Neuropathy Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 12.3.1. Peripheral Neuropathy
    • 12.3.2. Autonomic Neuropathy
    • 12.3.3. Proximal Neuropathy
    • 12.3.4. Focal Neuropathy
  • 12.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 12.4.1. Drugs
      • 12.4.1.1. Analgesics
        • 12.4.1.1.1. Topical
        • 12.4.1.1.1.1. Capsaicin
        • 12.4.1.1.1.2. Others
        • 12.4.1.1.2. Opioids
        • 12.4.1.1.2.1. Morphine
        • 12.4.1.1.2.2. Others
        • 12.4.1.1.3. NSAIDs
        • 12.4.1.1.3.1. Ibuprofen
        • 12.4.1.1.3.2. Naproxen
        • 12.4.1.1.3.3. Others
      • 12.4.1.2. Antidepressants
        • 12.4.1.2.1. TCAs
        • 12.4.1.2.1.1. Amitriptyline
        • 12.4.1.2.1.2. Imipramine
        • 12.4.1.2.1.3. Others
        • 12.4.1.2.2. SNRIs
        • 12.4.1.2.2.1. Duloxetine
        • 12.4.1.2.2.2. Others
        • 12.4.1.2.3. SSRIs
        • 12.4.1.2.3.1. Citalopram
        • 12.4.1.2.3.2. Paroxetin
        • 12.4.1.2.3.3. Others
      • 12.4.1.3. Anticonvulsants
        • 12.4.1.3.1. Gabapentin
        • 12.4.1.3.2. Pregabalin
        • 12.4.1.3.3. Topimarate
        • 12.4.1.3.4. Others
      • 12.4.1.4. Other Drugs
    • 12.4.2. Radiotherapy
      • 12.4.2.1. TENS
      • 12.4.2.2. Others
    • 12.4.3. Physiotherapy
  • 12.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.5.1. Hospitals
    • 12.5.2. Clinics
    • 12.5.3. Retail Pharmacies
    • 12.5.4. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Disorder Type
    • 12.7.2. By Treatment Type
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. Latin America Diabetic Neuropathy Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 13.3.1. Peripheral Neuropathy
    • 13.3.2. Autonomic Neuropathy
    • 13.3.3. Proximal Neuropathy
    • 13.3.4. Focal Neuropathy
  • 13.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 13.4.1. Drugs
      • 13.4.1.1. Analgesics
        • 13.4.1.1.1. Topical
        • 13.4.1.1.1.1. Capsaicin
        • 13.4.1.1.1.2. Others
        • 13.4.1.1.2. Opioids
        • 13.4.1.1.2.1. Morphine
        • 13.4.1.1.2.2. Others
        • 13.4.1.1.3. NSAIDs
        • 13.4.1.1.3.1. Ibuprofen
        • 13.4.1.1.3.2. Naproxen
        • 13.4.1.1.3.3. Others
      • 13.4.1.2. Antidepressants
        • 13.4.1.2.1. TCAs
        • 13.4.1.2.1.1. Amitriptyline
        • 13.4.1.2.1.2. Imipramine
        • 13.4.1.2.1.3. Others
        • 13.4.1.2.2. SNRIs
        • 13.4.1.2.2.1. Duloxetine
        • 13.4.1.2.2.2. Others
        • 13.4.1.2.3. SSRIs
        • 13.4.1.2.3.1. Citalopram
        • 13.4.1.2.3.2. Paroxetin
        • 13.4.1.2.3.3. Others
      • 13.4.1.3. Anticonvulsants
        • 13.4.1.3.1. Gabapentin
        • 13.4.1.3.2. Pregabalin
        • 13.4.1.3.3. Topimarate
        • 13.4.1.3.4. Others
      • 13.4.1.4. Other Drugs
    • 13.4.2. Radiotherapy
      • 13.4.2.1. TENS
      • 13.4.2.2. Others
    • 13.4.3. Physiotherapy
  • 13.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.5.1. Hospitals
    • 13.5.2. Clinics
    • 13.5.3. Retail Pharmacies
    • 13.5.4. Online Pharmacies
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Disorder Type
    • 13.7.2. By Treatment Type
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Diabetic Neuropathy Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 14.3.1. Peripheral Neuropathy
    • 14.3.2. Autonomic Neuropathy
    • 14.3.3. Proximal Neuropathy
    • 14.3.4. Focal Neuropathy
  • 14.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 14.4.1. Drugs
      • 14.4.1.1. Analgesics
        • 14.4.1.1.1. Topical
        • 14.4.1.1.1.1. Capsaicin
        • 14.4.1.1.1.2. Others
        • 14.4.1.1.2. Opioids
        • 14.4.1.1.2.1. Morphine
        • 14.4.1.1.2.2. Others
        • 14.4.1.1.3. NSAIDs
        • 14.4.1.1.3.1. Ibuprofen
        • 14.4.1.1.3.2. Naproxen
        • 14.4.1.1.3.3. Others
      • 14.4.1.2. Antidepressants
        • 14.4.1.2.1. TCAs
        • 14.4.1.2.1.1. Amitriptyline
        • 14.4.1.2.1.2. Imipramine
        • 14.4.1.2.1.3. Others
        • 14.4.1.2.2. SNRIs
        • 14.4.1.2.2.1. Duloxetine
        • 14.4.1.2.2.2. Others
        • 14.4.1.2.3. SSRIs
        • 14.4.1.2.3.1. Citalopram
        • 14.4.1.2.3.2. Paroxetin
        • 14.4.1.2.3.3. Others
      • 14.4.1.3. Anticonvulsants
        • 14.4.1.3.1. Gabapentin
        • 14.4.1.3.2. Pregabalin
        • 14.4.1.3.3. Topimarate
        • 14.4.1.3.4. Others
      • 14.4.1.4. Other Drugs
    • 14.4.2. Radiotherapy
      • 14.4.2.1. TENS
      • 14.4.2.2. Others
    • 14.4.3. Physiotherapy
  • 14.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.5.1. Hospitals
    • 14.5.2. Clinics
    • 14.5.3. Retail Pharmacies
    • 14.5.4. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Disorder Type
    • 14.7.2. By Treatment Type
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Johnson & Johnson (Janssen Global Services, LLC)
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Boehringer Ingelheim GmbH
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. NeuroMetrix, Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Eli Lilly and Company
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. GlaxoSmithKline plc
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Lupin Limited
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Pfizer Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Astellas Pharma Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Glenmark Pharmaceuticals Ltd.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Arbor Pharmaceuticals, LLC
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Depomed, Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview